Supraphysiologic-dose anabolic-androgenic steroid use: A risk factor for dementia?

NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

卷:100

Review

Kaufman, Marc J.^1,3  Kanayama, Gen^2,3  Hudson, James I.^2,3  Pope, Harrison G., Jr.^2,3 

[1] McLean Hosp, McLean Imaging Ctr, 115 Mill St,MS204, Belmont, MA 02478 USA

[2] McLean Hosp, Biol Psychiat Lab, 115 Mill St, Belmont, MA 02478 USA

[3] Harvard Med Sch, Dept Psychiat, Boston, MA 02115 USA

关键词: Aging;    Alcohol;    Alzheimer's disease;    Amyloid;    Anabolic-androgenic steroid;    ApoE;    Aquaporin 4;    alpha-secretase;    beta-secretase;    Body-building;    Boldenone;    Cannabis;    Cocaine;    Dementia;    Estrogen;    gamma-secretase;    GSK3 beta;    Heroin;    Homocysteine;    Hypogonadism;    Insomnia;    Insulin Degrading enzyme;    Low-density lipoprotein receptor-related;    protein 1;    Magnetic resonance imaging;    Magnetic resonance spectroscopy;    Menopause;    Methamphetamine;    Mild Cognitive Impairment;    Morphine;    Muscularity;    N-acetylcysteine;    Nandrolone;    Neprilysin;    Neurodegeneration;    Nrf2;    Opioid;    Oxidative stress;    Oxymetholone;    Performance-enhancing drugs;    PET imaging;    Polydrug use;    Prealbumin;    Presenilin;    Protein phosphatase 2A;    Scyllo-inositol;    Stanozolol;    tau;    Tobacco;    Sex-steroid;    Sleep disturbances;    Substance use disorder;    Testosterone;    Zinc;   

DOI  :  10.1016/j.neubiorev.2019.02.014

来源: Elsevier

【 摘 要 】

Supraphysiologic-dose anabolic-androgenic steroid (AAS) use is associated with physiologic, cognitive, and brain abnormalities similar to those found in people at risk for developing Alzheimer's Disease and its related dementias (AD/ADRD), which are associated with high brain beta-amyloid (A beta) and hyperphosphorylated tau (tauP) protein levels. Supraphysiologic-dose AAS induces androgen abnormalities and excess oxidative stress, which have been linked to increased and decreased expression or activity of proteins that synthesize and eliminate, respectively, A beta and tau-P. A beta and tau-P accumulation may begin soon after initiating supraphysiologic-dose AAS use, which typically occurs in the early 20s, and their accumulation may be accelerated by other psychoactive substance use, which is common among non-medical AAS users. Accordingly, the widespread use of supraphysiologic-dose AAS may increase the numbers of people who develop dementia. Early diagnosis and correction of sex-steroid level abnormalities and excess oxidative stress could attenuate risk for developing AD/ ADRD in supraphysiologic-dose AAS users, in people with other substance use disorders, and in people with low sex-steroid levels or excess oxidative stress associated with aging.

【 授权许可】

Free